Please use this identifier to cite or link to this item:
Title: Autoantibodies to transcription intermediary factor (TIF)1? associated with dermatomyositis
Author: Satoh, M.
Chan, J.Y.F.
Ross, S.J.
Li, Y.
Yamasaki, Y.
Yamada, H.
Mercado, M.V.-D.
Petri, M.H.
Jara, L.J.
Saavedra, M.A.
Cruz-Reyes, C.
Sobel, E.S.
Reeves, W.H.
Ceribelli, A.
Chan, E.K.L.
Issue Date: 2012
Abstract: Introduction: Myositis specific autoantibodies are associated with unique clinical subsets and are useful biomarkers in polymyositis/dermatomyositis (PM/DM). A 120 kD protein recognized by certain patients with DM was identified and clinical features of patients with this specificity were characterized.Methods: The 120 kD protein recognized by a prototype serum was purified and identified by mass spectrometry and immunological methods. Autoantibody to this 120 kD protein was screened in sera from 2,356 patients with various diagnoses from four countries, including 254 PM/DM, by immunoprecipitation of 35S-methionine labeled K562 cell extracts. Clinical information of patients with this specificity was collected.Results: The 120 kD protein, which exactly comigrated with PL-12, was identified as transcription intermediary factor TIF1? (TRIM28) by mass spectrometry and validated by immunoassays. By immunofluorescence, anti-TIF1? positivity showed a fine-speckled nuclear staining pattern. Four cases of anti-TIF1? were identified; all are women, one each in a Japanese, African American, Caucasian, and Mexican individual. Three had a diagnosis of DM and one case was classified as having an undifferentiated connective tissue disease with an elevated CPK but without significant muscle symptoms. This individual also had a history of colon cancer, cervical squamous metaplasia and fibroid tumors of the uterus. Myopathy was mild in all cases and resolved without treatment in one case. The anti-TIF1? specificity was not found in other conditions.Conclusions: Anti-TIF1? is a new DM autoantibody associated with a mild form of myopathy. Whether it has an association with malignancy, as in the case of anti-TIF1?, or other unique features will need to be evaluated in future studies. Zapotitlán 2012 Satoh et al.; licensee BioMed Central Ltd.
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.

Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.